Designing herpes viruses as oncolytics

by Cole Peters, Samuel D Rabkin
Published 2015-01-01

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma

by Dipongkor Saha, Samuel D Rabkin, Robert L Martuza
Published 2020-06-01

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

by Praveen K. Bommareddy, Samuel D. Rabkin, Howard L. Kaufman
Published 2019-04-01

Oncolytic viruses on the cusp of success?: proceedings of the 9th International Conference on Oncolytic Virus Therapeutics

by Cole Peters, Fares Nigim, E Antonio Chiocca, Samuel D Rabkin
Published 2016-01-01

Replication-Competent Herpes Simplex Virus Vector G207 and Cisplatin Combination Therapy for Head and Neck Squamous Cell Carcinoma

by Ali Chahlavi, Tomoki Todo, Robert L. Martuza, Samuel D. Rabkin
Published 1999-06-01

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma

by Praveen K. Bommareddy, Andrew Zloza, Samuel D. Rabkin, Howard L. Kaufman
Published 2019-07-01

In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV

by Nusrat Jahan, Shanawaz M. Ghouse, Robert L. Martuza, Samuel D. Rabkin
Published 2021-08-01

Ionizing Radiation Does Not Alter the Antitumor Activity of Herpes Simplex Virus Vector G207 in Subcutaneous Tumor Models of Human and Murine Prostate Cancer

by Timothy J. Jorgensen, Sanford Katz, Ellen K. Wittmack, Susan Varghese, Tomoki Todo, Samuel D. Rabkin, Robert L. Martuza
Published 2001-01-01

Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells

by Lei Wang, Jianfang Ning, Hiroaki Wakimoto, Shulin Wu, Chin-lee Wu, Melissa R. Humphrey, Samuel D. Rabkin, Robert L. Martuza
Published 2019-06-01

Combination of Oncolytic Herpes Simplex Viruses Armed with Angiostatin and IL-12 Enhances Antitumor Efficacy in Human Glioblastoma Models

by Wei Zhang, Giulia Fulci, Hiroaki Wakimoto, Tooba A. Cheema, Jason S. Buhrman, Deva S. Jeyaretna, Anat O. Stemmer Rachamimov, Samuel D. Rabkin, Robert L. Martuza
Published 2013-06-01

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma

by Jian-Fang Ning, Monica Stanciu, Melissa R. Humphrey, Joshua Gorham, Hiroko Wakimoto, Reiko Nishihara, Jacqueline Lees, Lee Zou, Robert L. Martuza, Hiroaki Wakimoto, Samuel D. Rabkin
Published 2019-07-01

Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma

by Ming Li, Guoping Li, Juri Kiyokawa, Zain Tirmizi, Leland G. Richardson, Jianfang Ning, Saumya Das, Robert L. Martuza, Anat Stemmer-Rachamimov, Samuel D. Rabkin, Hiroaki Wakimoto
Published 2020-12-01

An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma

by Esther Rheinbay, Mario L. Suvà, Shawn M. Gillespie, Hiroaki Wakimoto, Anoop P. Patel, Mohammad Shahid, Ozgur Oksuz, Samuel D. Rabkin, Robert L. Martuza, Miguel N. Rivera, David N. Louis, Simon Kasif, Andrew S. Chi, Bradley E. Bernstein
Published 2013-05-01

A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS)

by Ming-Ru Wu, Lior Nissim, Doron Stupp, Erez Pery, Adina Binder-Nissim, Karen Weisinger, Casper Enghuus, Sebastian R. Palacios, Melissa Humphrey, Zhizhuo Zhang, Eva Maria Novoa, Manolis Kellis, Ron Weiss, Samuel D. Rabkin, Yuval Tabach, Timothy K. Lu
Published 2019-06-01